• Reinaldo de Menezes Martins, Ana Luiza Braz Pavão, Patrícia Mouta Nunes de Oliveira, Paulo Roberto Gomes dos Santos, Sandra Maria D Carvalho, Renate Mohrdieck, Alexandre Ribeiro Fernandes, Helena Keico Sato, Patricia Mandali de Figueiredo, Vanessa Dos Reis von Doellinger, Maria da Luz Fernandes Leal, Akira Homma, and Maria de Lourdes S Maia.
• Bio-Manguinhos, Fiocruz, and CIFAVI (National Interinstitutional Committee for Pharmacovigilance in Vaccines and other Immunobiologicals), Brazil. Electronic address: rmenezes@bio.fiocruz.br.
• Vaccine. 2014 Nov 20; 32 (49): 6676-82.

AbstractNeurological adverse events following administration of the 17DD substrain of yellow fever vaccine (YEL-AND) in the Brazilian population are described and analyzed. Based on information obtained from the National Immunization Program through passive surveillance or intensified passive surveillance, from 2007 to 2012, descriptive analysis, national and regional rates of YFV associated neurotropic, neurological autoimmune disease, and reporting rate ratios with their respective 95% confidence intervals were calculated for first time vaccinees stratified on age and year. Sixty-seven neurological cases were found, with the highest rate of neurological adverse events in the age group from 5 to 9 years (2.66 per 100,000 vaccine doses in Rio Grande do Sul state, and 0.83 per 100,000 doses in national analysis). Two cases had a combination of neurotropic and autoimmune features. This is the largest sample of YEL-AND already analyzed. Rates are similar to other recent studies, but on this study the age group from 5 to 9 years of age had the highest risk. As neurological adverse events have in general a good prognosis, they should not contraindicate the use of yellow fever vaccine in face of risk of infection by yellow fever virus. Copyright © 2014 Elsevier Ltd. All rights reserved.

24 keywords...

hide…